Amgen (XSWX:AMGN) Price-to-Tangible-Book : (As of Apr. 25, 2024)

View and export this data going back to 2007. Start your Free Trial

What is Amgen Price-to-Tangible-Book?

As of today (2024-04-25), Amgen's share price is CHF179.83. Amgen's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was CHF-67.35. Hence, Amgen's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for Amgen's Price-to-Tangible-Book or its related term are showing as below:

During the past 13 years, Amgen's highest Price to Tangible Book Ratio was 73.95. The lowest was 22.27. And the median was 67.12.

XSWX:AMGN's Price-to-Tangible-Book is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 2.35
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, Amgen's share price is CHF179.83. Amgen's Book Value per Sharefor the quarter that ended in Dec. 2023 was CHF9.32. Hence, Amgen's P/B Ratio of today is 19.30.

Amgen Price-to-Tangible-Book Historical Data

The historical data trend for Amgen's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen Price-to-Tangible-Book Chart

Amgen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

Get a 7-Day Free Trial

Amgen Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Tangible-Book	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Amgen's Price-to-Tangible-Book

For the Drug Manufacturers - General subindustry, Amgen's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amgen's Price-to-Tangible-Book Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amgen's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Amgen's Price-to-Tangible-Book falls into.

Amgen Price-to-Tangible-Book Calculation

Amgen's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2023 )
	=	179.83	/	-67.351
	=

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Amgen Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Amgen's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Amgen (XSWX:AMGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (XSWX:AMGN) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

AMGN:USA AMG N:Mexico AMGd:UK 0R0T:UK AMG:Germany AMGN34:Brazil AMGN:Austria AMGN:Argentina

Address

One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799

Website

https://www.amgen.com

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.